

1 **TITLE:** Identification and Genomic Assessment of Daptomycin-, Linezolid-, Vancomycin-resistant

2 *Enterococcus faecium* During Protracted Infection

3

4 **RUNNING TITLE:** Evaluation of Multidrug Resistant *Enterococcus faecium* During Protracted Infection

5

6 **AUTHORS:** Nathan B. Pincus<sup>1\*</sup>, Tejas Joshi<sup>1\*</sup>, Samuel W.M. Gatesy<sup>2</sup>, Omar Al-Heeti<sup>2</sup>, W. Justin Moore<sup>3</sup>, and

7 Kelly E. R. Bachta<sup>2#</sup>

8

9 **AFFILIATIONS:**

10 <sup>1</sup> Feinberg School of Medicine, Northwestern University, Chicago, Illinois

11 <sup>2</sup> Division of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois

12 <sup>3</sup> Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois

13

14 \*Co-first authors

15 #Corresponding author: Kelly E. R. Bachta, [kelly.bachta@northwestern.edu](mailto:kelly.bachta@northwestern.edu)

16

17

18

19

20

21

22

23

24

25 **ABSTRACT**

26 Linezolid and daptomycin resistance among *Enterococcus faecium* (*Efm*) isolates, while rare, is a major  
27 challenge for clinicians who are often limited to broad-spectrum or combination antibiotic therapies for  
28 management. Combination therapy with a beta-lactam has been reported, but limited clinical evidence  
29 exists to support its use. We describe the clinical management of a prolonged *Efm* intraabdominal (IA)  
30 infection and subsequent bacteremia, along with observed multidrug resistance development and use of  
31 serial whole genome sequencing to better understand resistance mechanisms. Combination  
32 antimicrobial therapy with daptomycin (DAP) and ceftaroline (CPT) was used to treat the patient's  
33 catheter-associated daptomycin-, linezolid-, vancomycin-resistant *Efm* (DLVRE) bloodstream infection. *In*  
34 *vitro* antimicrobial testing of this DLVRE revealed only minor synergy between daptomycin and  
35 ceftaroline; However, the patient's bacteremia cleared following initiation of combination therapy in  
36 conjunction with catheter removal. Sequencing of the patient's DLVRE revealed multiple genomic  
37 mutations which explain both linezolid and daptomycin resistance and the presence of a plasmid  
38 containing known resistance determinants for vancomycin. Daptomycin resistance was attributed to the  
39 presence of chromosomal mutations in *liaS* (Thr120Ala), *liaR* (Trp73Cys), and *cls* (Asp13Ile), while linezolid  
40 resistance was attributed to the presence of the G2576T variant allele in some of 23S rRNA gene copies.  
41 Sequential whole genome sequencing of two additional bacterial isolates from the same patient revealed  
42 protracted colonization with a single DLVRE clone and suggested the development of bacterial  
43 subpopulations. Pairing clinical isolate susceptibilities with whole genome sequencing should be  
44 encouraged in clinical practice to better inform antimicrobial management in cases of multidrug  
45 resistance.

46

47 **KEYWORDS**

48 Vancomycin-resistant *Enterococcus faecium*, daptomycin-resistance, linezolid-resistance

## 49 INTRODUCTION

50 Multidrug resistant *Enterococcus faecium* (*Efm*) is an important cause of nosocomial infections including  
51 bacteremia, intraabdominal (IA) and urinary tract infections (UTIs). The incidence of enterococcal  
52 infections has increased steadily since the late 1970s (1) and enterococci are second only to *Escherichia*  
53 *coli* as a cause of nosocomial infection (2). In disease states, enterococci are believed to escape from the  
54 gastrointestinal (GI) tract, where they are natural colonizers and an important part of the GI microbiota  
55 (3). As GI tract residents, enterococci are frequently exposed to serial courses of antibiotics and have a  
56 remarkable ability to persist in part due to the plasticity of their genome (4). Antimicrobial resistance  
57 (AMR) arises through both genomic mutation and acquisition of mobile elements such as transposons and  
58 plasmids (5). Most enterococci demonstrate low-level intrinsic resistance to beta lactam antibiotics,  
59 moderate resistance to aminoglycosides and high resistance to most cephalosporins and clindamycin (6).  
60 Natural ampicillin resistance in *Efm* is largely attributed to penicillin-binding protein (PBP5) encoded by  
61 the bacterial chromosome, with variation in degree of resistance due to variable gene expression (7, 8)  
62 and the presence of a low-affinity allele associated with increased levels of resistance in the dominant  
63 hospital-associated *Efm* clade (1, 9, 10). Vancomycin resistance is driven by replacement of the terminal  
64 D-alanine residue of peptidoglycan precursors with either D-lactate or D-serine (3, 11). These altered  
65 peptidoglycan fragments are generated through expression of multiple gene clusters (*van* operons) which  
66 can be present on either the chromosome or transferable mobile plasmids (11).

67 Treatment of VRE often requires the use of newer antimicrobial agents including linezolid (LZD)  
68 and daptomycin (DAP) (12, 13). Though overall resistance remains rare (<1% for linezolid and <2% for  
69 daptomycin) (14, 15), resistance to both agents emerged shortly after these antibiotics were clinically  
70 introduced and is rising steadily (12, 15-19). Specifically, linezolid resistance is mediated by both  
71 chromosomal mutations and gene acquisition. Resistance to linezolid is linked to mutations in 23S  
72 ribosomal RNA genes and acquisition of plasmid-borne genes *cfr* and *optrA* encoding a ribosomal

73 methyltransferase and an ATP-binding cassette transporter, respectively (15). Enterococcal resistance to  
74 daptomycin is more common in *Efm* than *E. faecalis* (1, 14), and resistance has been linked to mutations  
75 in two major groups of genes. The first (*liaFSR* and *yycFGHIJ*) encodes regulatory pathways that  
76 coordinate the stress response of the bacterial cell envelope. The second encodes enzymes that  
77 metabolize phospholipids, including glycerophosphoryl diester phosphodiesterase (*gdpD*) and cardiolipin  
78 synthetase (*cls*) (20, 21). The understanding of both linezolid and daptomycin resistance in enterococci  
79 continues to evolve (15, 20, 21).

80         Although they represent <1% of all enterococcal infections, the prevalence of daptomycin-,  
81 linezolid-, and vancomycin-resistant *Efm* (DLVRE) is increasing (14, 15, 22). Risk factors associated with  
82 the development of DLVRE include neutropenia, invasive procedures and cumulative antibiotic exposure,  
83 notably exposure to daptomycin, within the past year (23, 24). There are limited data on efficacious  
84 treatments for such infections. Combination therapy of daptomycin and a beta lactam antibiotic is  
85 thought to act synergistically to sensitize the bacterial cell membrane and improve the penetration of  
86 daptomycin (25). This combination is being explored for treatment (26, 27). *In vitro* studies with VRE  
87 revealed that ceftaroline (CPT) increased the bactericidal activity of daptomycin and lowered the  
88 daptomycin minimal inhibitory concentration (MIC) when co-administered (27-30). However, data are  
89 limited on the impact of dual antimicrobial therapy on clinical outcomes of patients with DLVRE infections.

90         Here, we report successful treatment of DLVRE catheter-associated bloodstream infection  
91 (CLABSI) in the setting of protracted IA abscess. We applied whole genome sequencing to characterize  
92 the genetic changes underlying emerging linezolid and daptomycin resistance in this case of persistent  
93 infection.

94

## 95 **METHODS**

### 96 **Antimicrobial Resistance Testing**

97 Antimicrobial resistance testing was performed at Northwestern Memorial Hospital and Northwestern  
98 University using the Vitek2 platform (bioMerieux) and Epsilometer testing (E- test). Additional synergy  
99 testing was performed on Mueller Hinton II (MHII) agar using E-test strips (Lisofilchem s.r.l). Briefly,  
100 bacteria were grown overnight at 37°C on blood agar plates. A suspension at optical density 600 (OD 600)  
101 of 0.08 to 0.1 was created by resuspending bacterial colonies in phosphate buffered saline (PBS). This  
102 suspension was subsequently confluent spread across the surface of a MHII agar plate. Plates were  
103 dried for five minutes and then a single DAP E-test strip was placed in the center of the plate and incubated  
104 for ten minutes. This DAP E-test strip was then removed and saved. In the same location and orientation  
105 as the DAP E-test, a CPT E-test strip was placed and the original DAP E-test strip replaced directly on-top  
106 (31). DAP and CPT single E-test controls were laid side-by-side on the same plates. The plates were  
107 incubated at 37°C for 24 hours, and the minimal inhibitor concentrations (MIC) were interpreted.

108

#### 109 **Whole genome sequencing and genome assembly**

110 Genomic DNA from Isolate 3 was isolated from a single colony grown overnight in 5 mL of tryptic soy broth  
111 using the Promega Maxwell 16 instrument. A short-read sequencing library was prepared with a  
112 plexWell™ 96 kit (seqWell), and sequencing was performed on an Illumina MiSeq with a v3 reagent kit  
113 yielding 709,596 301 bp paired-end reads totaling 427 Mbp. Illumina reads were quality trimmed using  
114 Trimmomatic v0.36 (32), resulting in 450,275 paired-end reads totaling 179 Mbp of sequence for  
115 approximate genomic coverage of 60-fold. Long-read sequencing was performed on the MinION platform  
116 with a FLO-MIN106 flow cell after library preparation with an Oxford Nanopore SQK-LSK109 ligation  
117 sequencing kit. Base calling and read-quality filtering was performed using Guppy v3.4.5 with the R9.4.1  
118 high-accuracy model, yielding 248,837 reads totaling 1,339 Mbp. Using Filtrlong v0.2.0, Nanopore reads  
119 were filtered to retain the best 95% of sequence with a minimum read length of 1000 bp, yielding 196,162  
120 reads totaling 1,272 Mbp of sequence for an approximate coverage of 424-fold. Hybrid genome assembly

121 was performed based on trimmed Illumina reads and filtered nanopore reads using Unicycler v0.4.8 (33)  
122 with default settings. The resulting complete genome was annotated using the NCBI Prokaryotic Genome  
123 Annotation Pipeline v5.3 (34). *In silico* sequence typing was performed by comparing our existing  
124 genomic sequences to *Efm* allele sequences and MLST profiles obtained from the PubMLST database (35).  
125 Isolate 3 plasmid replicons were identified using PlasmidFinder v2.1 (36) and compared to previously-  
126 described plasmids by BLAST search against *Enterococcus* sequences in the NCBI nt database.

127 Genomic DNA preparation and short-read sequencing library preparation for Isolates 4 and 5 were  
128 performed as described above. Sequencing was performed on an Illumina NovaSeq instrument yielding  
129 150 bp paired-end reads totaling 162 Mbp for Isolate 4 and 316 Mbp for Isolate 5. Read trimming was  
130 performed as described above yielding 118 Mbp of sequence for Isolate 4 for an approximate coverage of  
131 39-fold and 233 Mbp of sequence for isolate 5 for an approximate coverage of 78-fold. Draft genomes of  
132 Isolate 4 and 5 were assembled using SPAdes v3.9.1 with careful and automatic read coverage cutoff  
133 options (37) and filtered to remove contigs less than 200 bp or 5-fold mean coverage. Draft genomes  
134 were annotated using the NCBI Prokaryotic Genome Annotation Pipeline v5.3 (34). *In silico* sequence  
135 typing was performed as described above.

136

### 137 **Antimicrobial resistance gene identification**

138 Known single nucleotide variants (SNVs) and acquired genes associated with AMR were identified in  
139 assembled genomes using AMRFinderPlus v3.10.16 (38) and ResFinder v4.1 (39). Illumina reads were  
140 screened for the presence of linezolid resistance mechanisms, including 23S rRNA gene variations and  
141 acquired genes, using LRE-Finder v1.0 (40).

142

## 143 **Pairwise genome comparisons**

144 Isolates 4 and 5 were aligned to the Isolate 3 complete genome and SNVs between strains were identified  
145 as previously described (41). Briefly, trimmed Illumina reads were aligned to the Isolate 3 chromosome  
146 and plasmids using BWA v0.7.15 (<https://arxiv.org/abs/1303.3997v2>) and the resulting alignments sorted  
147 and indexed using samtools v0.1.19-44428cd (42). SNV calling from these alignments was performed  
148 using bcftools\_filter.pl ([https://github.com/egonozer/bcftools\\_filter](https://github.com/egonozer/bcftools_filter)). To better understand the genetic  
149 context of missing AMR genes in the Isolate 4 draft genome, Isolate 4 and 5 draft genome contigs were  
150 aligned to plasmid 3 of Isolate 3 using BRIG v0.95 (43).

151

## 152 **Data availability**

153 Sequencing and genome assemblies have been deposited to NCBI under BioProject accession number  
154 PRJNA787599, with Isolate 3 termed NMVRE-001 (SAMN23828484), Isolate 4 termed NMVRE-002  
155 (SAMN23828912), and Isolate 5 termed NMVRE-003 (SAMN23828937). Reads are available under SRA  
156 accessions SRR17230443-SRR17230446. Assemblies are available under GenBank accessions  
157 GCA\_021228615.1, GCA\_021364775.1, and GCA\_021364755.1.

158

## 159 **Bioethics Statement**

160 This research study (STU00214816) was submitted for review to the Northwestern University Institutional  
161 Review Board and, because of the retrospective nature of this work, was deemed “research that does not  
162 involve human subjects”. Further IRB review and approval was, therefore, not required. In good faith,  
163 the case report was discussed openly with the patient in question and the patient verbally consented to  
164 its publication.

165

166

## 167 RESULTS

### 168 Case Presentation

169 A middle-aged patient with a history of small bowel obstruction requiring multiple laparoscopic  
170 abdominal surgeries presented to our institution for elective incisional hernia repair. The patient  
171 underwent lysis of adhesions and small bowel resection with primary anastomosis and mesh closure. The  
172 patient's post-operative course was complicated by the development of loculated IA abscesses secondary  
173 to an enteric leak at the anastomotic site. A drain was placed into the largest abscess and aspiration  
174 cultures were obtained on post-operative day (POD) 10 revealing a polymicrobial abscess including  
175 *Escherichia coli*, *Enterococcus faecalis*, coagulase-negative *Staphylococcus*, *Streptococcus constellatus*,  
176 *Candida albicans* and vancomycin-resistant *Efm* (Table 1, Isolate 1, VRE). Given an allergy to penicillin,  
177 the patient was initially treated with aztreonam and metronidazole. When cultures returned, the patient  
178 was transitioned to culture-directed therapy (meropenem, fluconazole and linezolid) for four weeks  
179 (Figure 1). At the completion of this course, clinical and radiographic improvement was achieved.

180 Four days after stopping antibiotics (POD 50), the patient developed recurrent abdominal pain  
181 and leukocytosis of 26.6K cells/ $\mu$ L. Meropenem, fluconazole and daptomycin were initiated. Daptomycin  
182 was chosen out of concern for long-term linezolid toxicity. Repeat IA cultures on POD 50 demonstrated a  
183 new linezolid resistant-VRE (Table 1, Isolate 2, LVRE). The patient was ultimately treated with intravenous  
184 ceftriaxone, fluconazole and daptomycin. On POD 73, following an episode of emesis directly onto an  
185 existing right brachial peripherally inserted central catheter (PICC), the patient developed a fever. Blood  
186 cultures from the periphery and PICC line both revealed new daptomycin resistant-LVRE (Table 1, Isolate  
187 3, DLVRE). The PICC line was removed and blood cultures cleared the following day. Ceftaroline was  
188 added when the daptomycin non-susceptibility results became available. After one week of combination



189 antimicrobial therapy, the patient had radiographic decrease in the size of the IA abscess, resolution of  
190 leukocytosis and reduction of fevers. The patient was discharged home on POD 86 off antibiotics.

191 Five weeks after discharge (POD 122), the patient was readmitted with left lower quadrant (LLQ)  
192 abdominal pain and increased drainage from around an abdominal drain site. CT scan revealed an  
193 additional abdominal wall fluid collection for which the patient underwent incision and drainage. Again,  
194 cultures were polymicrobial growing *Klebsiella oxytoca*, *Enterobacter cloacae*, *Streptococcus anginosus*,  
195 *E. coli*, *E. faecalis* and DLVRE (Table 1, Isolate 4). The patient was diagnosed with an enterocutaneous  
196 fistula and briefly treated with ceftriaxone followed by cefepime. In an effort to spare the patient  
197 prolonged courses of broad-spectrum antibiotics and in light of the patient's clinical stability, the patient  
198 was discharged home off of all antibiotics on POD 128.

199 The patient was readmitted again on POD 169 following a fall. While hospitalized, the patient  
200 developed a new leukocytosis to 16.4K cells/ $\mu$ L, worsening LLQ abdominal tenderness and erythema. An  
201 abdominal CT scan demonstrated a new 5.8 cm abscess in the left anterior abdominal wall. The abscess  
202 was drained and cultures grew *Pseudomonas aeruginosa*, *K. oxytoca*, *E. cloacae*, *C. albicans* and DLVRE  
203 (Table 1, Isolate 5). The patient received a 10-day course of antimicrobials including cefepime, linezolid,  
204 metronidazole and fluconazole. Of note, Isolate 5 was initially reported as susceptible to linezolid (MIC of  
205 2  $\mu$ g/mL on VITEK2 platform); However, upon confirmatory testing, Isolate 5 was determined to be  
206 resistant to linezolid with an MIC of 12  $\mu$ g/mL by E-test (Table 1, Isolate 5). Despite this discrepancy, the  
207 patient's clinical status improved as erythema, abdominal tenderness and leukocytosis resolved. After  
208 one week of inpatient observation off antibiotics, the patient was discharged home on POD 187. A  
209 detailed course of antimicrobial therapy is outlined in Figure 1.

210

211 **In vitro synergy testing reveals little synergy between DPT and CPT**

212 Given that the patient's CLABSI was secondary to DLVRE (Isolate 3) leaving limited options for therapy, we  
213 chose to empirically start combination therapy with daptomycin and ceftaroline (25-27, 30). We sought  
214 to validate our antimicrobial choice *in vitro* by conducting synergy antimicrobial resistance testing (31).  
215 Confirmatory testing (E-test) in the laboratory revealed individual MICs to daptomycin of 16 µg/mL and  
216 ceftaroline of 32 µg/mL. Synergy testing in the experimental laboratory revealed only modest synergy,  
217 with the addition of ceftaroline lowering the daptomycin MIC from 16 to 12 µg/mL (Fig. 2). Addition of  
218 ceftaroline did not change the clinical interpretation of daptomycin resistance in Isolate 3 (44).

219

### 220 **Genomic evaluation of antimicrobial resistance in Isolate 3**

221 We sought to use genomics to understand the mechanisms behind evolving drug-resistance in our DLVRE  
222 isolates. Unfortunately, we did not have access to Isolates 1 and 2 for comparison as they had been  
223 previously discarded. Whole genome sequencing of Isolate 3 confirmed the identity of a sequence type  
224 (ST) 584 *Efm*. ST584 is a member of the pandemic clonal complex 17 (CC17) that includes a collection of  
225 hospital-acquired *Efm* sequence types (45-47). The complete genome of Isolate 3 included a single  
226 chromosome of 2.8 Mbp and 5 plasmids of lengths 228.3 Kbp (p1), 50.1 Kbp (p2), 40.6 Kbp (p3), 11.9 Kbp  
227 (p4), and 1.9 Kbp (p5), respectively. The sequence present in these plasmids was similar to that previously  
228 described in *Efm* plasmids, although present in different configurations. For example, nearly all of the  
229 sequence present in plasmids 2 and 4 has been described in substantially larger, previously described  
230 plasmids (Supplementary Table S1) reaffirming that *Efm* plasmids are highly modular (48).

231 Examination of the complete genome of Isolate 3 for known antimicrobial resistance  
232 determinants reasonably explained the observed susceptibility pattern (Table 2). Isolate 3 contained the  
233 low-affinity penicillin-binding protein 5 allele (*pbp5-R*) found in the *Efm* nosocomial clade, clade A, that is  
234 associated with ampicillin resistance (1, 9, 10). On the 40.6kb p3, we identified the presence of a *vanA*  
235 operon (Figure 3), explaining the observed vancomycin resistance. The *vanA* operon was flanked by

236 IS1216 family transposases, consistent with the known presence of *vanA* operons on plasmid-borne  
237 *Tn1546*-type transposons (49). Daptomycin resistance was attributed to the presence of chromosomal  
238 mutations in *liaS* (Thr120Ala), *liaR* (Trp73Cys) and *cls* (Asp13Ile). Other resistance mechanisms identified  
239 included fluoroquinolone resistance mutations, *gyrA* (Ser83Tyr) and *parC* (Ser80Arg), aminoglycoside  
240 resistance genes *aac(6')-I*, *aph(3')-IIIa* and *ant(6)-Ia*, trimethoprim resistance genes *dfpG* and *dfpF* and  
241 tetracycline resistance genes *tetL* and *tetM* (Table 2).

242 The mechanism of linezolid resistance for Isolate 3 was not immediately apparent from  
243 interrogation of its complete genome sequence. However, a read-based analysis (40) estimated that  
244 Isolate 3 contained three copies of the variant G2576T allele in the six copy 23S rRNA gene (48% of aligned  
245 reads contained the G2576T variant allele). The absence of these variants in the complete genome was  
246 likely an artifact of the assembly method, which used nanopore reads to bridge short-read derived contigs  
247 (33), combined with the fact that they were present in only some copies of a multi-copy gene. Variant  
248 alleles in the 23S rRNA gene, particularly G2576T, are the most common mechanism of linezolid resistance  
249 in *Efm* (15). The level of linezolid resistance correlates with the number of variant alleles (40, 50). Other  
250 determinants associated with acquired linezolid resistance, including the 23S rRNA methyltransferase  
251 gene *cfr* and the ATP-binding cassette ABC-F gene *optrA*, were not present in the genome (Table 2).

252

### 253 **Evolution of *Enterococcus faecium* during protracted infection**

254 Given the patient's repeated admissions and repeated isolation of DLVRE, we chose to perform short-read  
255 sequencing on two additional *Efm* Isolates, Isolates 4 and 5. Isolates 4 and 5 were both clonal with Isolate  
256 3 and belonged to the same sequence type, ST584. Isolate 4 had 2 chromosomal SNVs with respect to  
257 Isolate 3, while Isolate 5 had 13 chromosomal and 3 p1 SNVs (Supplementary Table S2). All SNVs present  
258 in Isolate 5 were previously observed in Isolate 4. While Isolate 4's SNVs were located in intergenic  
259 regions, Isolate 5 also contained SNVs in predicted protein coding genes (Supplementary Table S3).

260 Altogether, these findings strongly suggest persistent infection, or colonization with recurrent infection,  
261 by a specific DLVRE clone.

262 Isolates 4 and 5 contained the same elements associated with resistance to ampicillin,  
263 vancomycin, and daptomycin. Similar to Isolate 3, Isolate 4 contained an estimated three copies of the  
264 23S rRNA gene containing the G2576T variant allele (56% G2576T), likely leading to observed linezolid  
265 resistance. Isolate 5, on the other hand, was estimated to encode two copies of the 23S rRNA gene  
266 containing the G2576T variant allele (33% G2576T) (Table 2). As previously stated (40, 50), copy number  
267 of the G2576T variant allele correlates with level of resistance, potentially explaining the lower linezolid  
268 MIC seen in Isolate 5 (Table 1). There may be other contributing factors given the substantially different  
269 MICs between Isolates 3 and 4 despite each possessing the same number of mutant alleles.

270 While the other 4 plasmids were fairly well conserved between Isolates 4 and 5 and Isolate 3, we  
271 noted the absence of a substantial portion of p3 in Isolate 4 (Figure 3, Supplementary Table S2), resulting  
272 in the loss of resistance genes *ermB*, *ant(6)*, *sat4*, and *aph(3')-IIIa* (Table 2, Figure 3). This deletion of  
273 approximately 7.4 Kbp was notably flanked by IS1216 family transposase genes, suggesting that it was  
274 located on a mobile element. Interestingly, this sequence was present in Isolate 5 (Figure 3). This implies  
275 that multiple subpopulations of this ST584 DLVRE clone developed during our case of protracted infection,  
276 as the intact p3 would need to be present on POD 122 when Isolate 4 was collected to be found again in  
277 subsequent Isolate 5 on POD 169.

278

## 279 **DISCUSSION**

280 In this study, a patient with an IA abscess known to harbor VRE developed DLVRE bacteremia following  
281 prolonged sequential treatment with linezolid and daptomycin. Ultimately, the patient experienced an  
282 episode of CLABSI secondary to DLVRE. Limited data exist on appropriate antibiotic choice in such

283 challenging clinical situations (16, 24). Based on prior clinical and experimental data (25-27, 29, 30), we  
284 elected to use daptomycin in conjunction with ceftaroline for synergy, and the patient achieved a desired  
285 clinical response: clearance of blood cultures and diminishing size of an IA abscess. To our knowledge,  
286 this is the first case report demonstrating a successful clinical outcome with the use of daptomycin and  
287 beta-lactam antimicrobial therapy for CLABSI associated with IA abscesses. In our case, it is difficult to  
288 delineate if successful treatment of bacteremia was achieved due to the removal of an infected central  
289 line, dual antimicrobial therapy or the combination of both. The generalizability of this combination  
290 approach is also limited by our experiences in a single patient. These results point to the need for further  
291 evaluation of daptomycin and beta-lactam antimicrobial combination therapy for DLVRE infections in  
292 larger clinical studies. This case also highlights the challenges of determining appropriate duration of  
293 antibiotics when a polymicrobial abscess persists. Our patient ultimately received a total of 57 days of  
294 broad-spectrum antibiotics. Repeat cultures revealed the development of progressive antimicrobial  
295 resistance over time and, despite our best stewardship efforts, the patient's symptoms recurred. This  
296 outcome underscores the challenges that clinicians face when deploying culture-directed therapy in  
297 patients with protracted infectious reservoirs. In settings where complete source control is not  
298 achievable, there seems to be no clear answer on antibiotic choice or duration.

299         With the rise in VRE infections, clinicians are increasingly reliant on reserved antibiotic therapies  
300 such as daptomycin and linezolid as the backbone of successful treatment. By deploying whole-genome  
301 sequencing in a series of DLVRE isolates separated by 13 weeks, we were able to determine genetic  
302 explanations for the observed vancomycin, daptomycin and linezolid resistant phenotypes in our isolates.  
303 Our work, in conjunction with others, demonstrates the utility of whole-genome sequencing longitudinal  
304 samples during prolonged infection to map genomic changes responsible for acquired AMR (17, 22).  
305 Given the observation that there was plasmid heterogeneity in p3 between Isolates 3 and 5 and Isolate 4,  
306 our also work suggests that there are likely subpopulations of *Efm* that develop during protracted

307 infection. Plasmid 3 was virtually identical in Isolates 3 and 5, which are separated by 96 days, but was  
308 missing a substantial segment in Isolate 4 which was isolated temporally between Isolates 3 and 5. The  
309 idea of a single species bacterial “cloud of diversity” in prolonged infection is not new, but the impact of  
310 this diversity on successful antimicrobial treatment and infection outcome is clinically underappreciated  
311 (4, 51, 52). We have shown that subpopulations may possess different armamentariums of AMR genes  
312 and vary in degree of resistance. These observations are missed by traditional methods of AMR detection,  
313 making targeted treatment decisions based on such methods problematic. Phenotypic resistance analysis  
314 from an isolated colony may mask small subpopulations that harbor more difficult-to-treat antimicrobial  
315 resistant phenotypes and lead to suboptimal antimicrobial therapy decisions.

316         With the increasing rates of MDR *Efm* infections, it is critical that we understand how *Efm* adapts  
317 to prolonged antimicrobial pressure and recognize that traditional clinical resistance testing may not  
318 mirror population level AMR phenotypes. Further work is needed to elucidate the best course of  
319 treatment for patients with VRE requiring long-term antibiotic therapy and for those who develop MDR  
320 *Efm* while on therapy (24). Synergy testing is currently not available in most clinical laboratories. Our  
321 study highlights the urgent need for rapid implementation of investigational MIC testing paired with  
322 genomic analysis to successfully support real-time clinical decision making.

323 **ACKNOWLEDGMENTS**

324 This work was supported by grants from the National Institutes of Health (NIH)/National Institute of  
325 General Medical Sciences (NIGMS) (T32 GM008152 awarded to N.B.P), an American Cancer Society (ACS)  
326 Clinician Scientist Development Grant (#134251-CSDG-20-053-01-MPC, awarded to K.E.R.B.), and a  
327 Northwestern University Emerging and Re-emerging Pathogen Program (EREPP) grant (awarded to  
328 K.E.R.B.). This work was also supported by the Northwestern Memorial Clinical Microbiology laboratory  
329 and the NUSeq Core Facility which is generously supported by the NCI CCSG P30 CA060553 award to the  
330 Robert H. Lurie Comprehensive Cancer Center. This work was supported in part through the  
331 computational resources and staff contributions provided by the Genomics Compute Cluster which is  
332 jointly supported by the Feinberg School of Medicine, the Center for Genetic Medicine, and Feinberg's  
333 Department of Biochemistry and Molecular Genetics, the Office of the Provost, the Office for Research,  
334 and Northwestern Information Technology. The Genomics Compute Cluster is part of Quest,  
335 Northwestern University's high-performance computing facility, with the purpose to advance research in  
336 genomics. The funders had no role in study design, data collection and analysis, decision to publish, or  
337 preparation of the manuscript. We would like to thank members of the Hauser and Ozer laboratories for  
338 their valuable comments during numerous discussions of this work.


339

340

341 **FIGURES and TABLES**

343






344

345 **FIGURE 1 Timeline of antimicrobial treatment and *E. faecium* isolate recovery.** Post-operative day and *Efm* isolate recovery profiles (V,  
 346 vancomycin; L, linezolid, D, daptomycin; bottom) are shown together with antibiotic and antifungal treatment regimens. Vancomycin-resistant  
 347 enterococci (VRE) targeted antimicrobials are highlighted in orange and other antimicrobials are presented in light grey. Isolate post-operative  
 348 day recovery dates are highlighted in blue. Inverted carrots signify that the antimicrobial agent in question was continued throughout the time  
 349 period in question. Two vertical forward slashes denote time breaks.

350

**A**



**B**



351

352


353 **FIGURE 2 Synergy susceptibility testing of *Efm* Isolate 3.** (A) DAP E-test of isolate 3 (16 µg/mL). (B)

354 Combination E-testing of DAP and CPT of Isolate 3 (DAP MIC 12 µg/mL). Synergy was tested by first

355 applying a DAP E-test to the plate, removing it, applying a CPT E-test on the exact same location, and

356 placing the DAP E-test directly on top to read the susceptibility to DAP in the presence of CPT.

357



358

359 **FIGURE 3** Alignment of plasmid 3 from Isolates 4 and 5 to the vancomycin resistance plasmid 3 of

360 **Isolate 3**. Regions present in Isolate 4 and 5 draft genomes are indicated in purple and green

361 respectively. Identified resistance genes are indicated in black.

363 **TABLE 1** Minimal Inhibitory Concentrations (MICs  $\mu\text{g}/\text{mL}$ ) for the patient's isolates of *Efm*

Antibiotic	Isolate 1 (VRE)	Isolate 2 (LVRE)	Isolate 3 <sup>b</sup> (DLVRE)	Isolate 4 <sup>b</sup> (DLVRE)	Isolate 5 <sup>b</sup> (DLVRE)
Ampicillin	$\geq 32$ R	$\geq 32$ R	$\geq 32$ R	$\geq 32$ R	$\geq 32$ R
Daptomycin	--	2 SDD	12 R <sup>a</sup>	16 R <sup>a</sup>	16 R <sup>a</sup>
Linezolid	2 S	128 R <sup>a</sup>	48 R <sup>a</sup>	>256 R <sup>a</sup>	12 R <sup>a</sup>
Vancomycin	$\geq 32$ R	$\geq 32$ R	$\geq 32$ R	$\geq 32$ R	$\geq 32$ R

364 R, resistant; S, susceptible; SDD, susceptible dose dependent; --, not reported.

365 <sup>a</sup>MICs determined by E-testing assays.

366 <sup>b</sup>Sequenced isolate.

369 **TABLE 2 Genomic mechanisms of antimicrobial resistance identified in Isolates 3, 4, and 5.**

Antibiotic	Resistance Determinants	Location in Isolate 3	Isolate 3	Isolate 4	Isolate 5
Ampicillin	<i>pbp5</i> (Val24Ala, Ser27Gly, Arg34Gln, Gly66Glu, Ala68Thr, Glu85Asp, Glu100Gln, Lys144Gln, Thr172Ala, Leu177Ile, Asp204Gly, Ala216Ser, Thr324Ala, Met485Ala, Asn496Lys, Ala499Thr, Glu525Asp, Glu629Val, Pro667S)	Chromosome	+	+	+
Linezolid	23S rRNA gene G2576T	Chromosome	3/6 copies	3/6 copies	2/6 copies
Daptomycin	<i>liaS</i> (Thr120Ala)	Chromosome	+	+	+
	<i>liaR</i> (Trp73Cys)	Chromosome	+	+	+
	<i>cls</i> (Asp13Ile)	Chromosome	+	+	+
Vancomycin	<i>vanHAX</i>	Plasmid 3	+	+	+
	<i>vanSR</i>	Plasmid 3	+	+	+
	<i>vanZY</i>	Plasmid 3	+	+	+
Fluoroquinolones	<i>gyrA</i> (Ser83Tyr)	Chromosome	+	+	+
	<i>parC</i> (Ser80Arg)	Chromosome	+	+	+
Aminoglycosides	<i>aac(6')-I</i>	Chromosome	+	+	+
	<i>aph(3')-IIIa</i>	Plasmid 3	+	-	+
	<i>ant(6)-Ia</i>	Plasmid 3	+	-	+
Trimethoprim	<i>dfrF</i>	Chromosome	+	+	+
	<i>dfrG</i>	Chromosome	+	+	+
Tetracyclines	<i>tetL</i>	Chromosome	+	+	+
	<i>tetM</i>	Chromosome	partial and complete copy	partial copy	partial copy
Streptothricin	<i>sat4</i>	Plasmid 3	+	-	+
Macrolides	<i>msrC</i>	Chromosome	+	+	+
	<i>ermB</i>	Plasmid 3	+	-	+

371 **SUPPLEMENTARY TABLE S1 Characterization of Isolate 3 plasmids.**

Plasmid	Length (bp)	Replicon	Representative Similar Plasmid <sup>a</sup>				PMID Reference
			GenBank Accession	Length	Query Coverage (%)	Query Identity (%)	
1	228311	repUS15	CP064425.1	203164	80	99.96	33332354
2	59066	unknown	CP012468.1	84196	92	100	28301471
3	40605	rep17	CP076330.1	40559	95	99.87	34747439
4	11983	rep29	CP065776.1	27166	99	99.16	33895846
5	1928	rep14a (partial)	CP064442.1	1928	100	100	33332354

372 <sup>a</sup>Based on BLAST search against *Enterococcus* sequences in the NCBI nt database

373

374 **SUPPLEMENTARY TABLE S2 Alignment of Isolate 4 and 5 to the Isolate 3 Complete Genome.**

Isolate	Chromosome		p1		p2		p3		p4		p5	
	Percent Alignment <sup>a</sup>	SNVs	Percent Alignment <sup>a</sup>	SNVs	Percent Alignment <sup>a</sup>	SNVs	Percent Alignment <sup>a</sup>	SNVs	Percent Alignment <sup>a</sup>	SNVs	Percent Alignment <sup>a</sup>	SNVs
4	95.0	2	98.7	0	100	0	78.3	0	90.0	0	100	0
5	96.1	13	99.1	3	100	0	98.9	0	92.5	0	100	0

375 <sup>a</sup>Percentage of total length of covered by aligned sequences with a minimum depth cutoff of 5 reads.

376 **SUPPLEMENTARY TABLE S3 SNVs Detected in Alignment of Isolate 4 and 5 to the Isolate 3 Complete**

377 **Genome**

Location	Site	Annotation in Isolate 3	Isolate 4	Isolate 5
Chromosome	89200	intergenic	-	+
Chromosome	232118	cation-translocating P-type ATPase	-	+
Chromosome	413477	intergenic	+	+
Chromosome	1016951	cardiolipin synthase	-	+
Chromosome	1125507	NAD(P)/FAD-dependent oxidoreductase	-	+
Chromosome	1208228	<i>rsmD</i>	-	+
Chromosome	1263527	branched-chain amino acid aminotransferase	-	+
Chromosome	1342358	ABC transporter substrate-binding protein	-	+
Chromosome	1887988	intergenic	+	+
Chromosome	1896892	Xaa-Pro peptidase family protein	-	+
Chromosome	2107572	alpha/beta fold hydrolase	-	+
Chromosome	2547067	intergenic	-	+
Chromosome	2720433	pseudogene	-	+
p1	167	<i>repA</i>	-	+
p1	120818	HAMP domain-containing histidine kinase	-	+
p1	177993	Heavy metal translocating P-type ATPase	-	+

378

379

380

381

382



383 **REFERENCES**

- 384 1. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance. *Nat Rev*  
385 *Microbiol* 10:266-78.
- 386 2. Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM. 2016.  
387 Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary  
388 of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control  
389 and Prevention, 2011-2014. *Infect Control Hosp Epidemiol* 37:1288-1301.
- 390 3. Fisher K, Phillips C. 2009. The ecology, epidemiology and virulence of Enterococcus. *Microbiology*  
391 (Reading) 155:1749-1757.
- 392 4. Dubin KA, Mathur D, McKenney PT, Taylor BP, Littmann ER, Peled JU, van den Brink MRM, Taur Y,  
393 Pamer EG, Xavier JB. 2019. Diversification and Evolution of Vancomycin-Resistant *Enterococcus*  
394 *faecium* during Intestinal Domination. *Infect Immun* 87.
- 395 5. Paulsen IT, Banerjee L, Myers GS, Nelson KE, Seshadri R, Read TD, Fouts DE, Eisen JA, Gill SR,  
396 Heidelberg JF, Tettelin H, Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S, DeBoy RT,  
397 Durkin S, Kolonay J, Madupu R, Nelson W, Vamathevan J, Tran B, Upton J, Hansen T, Shetty J,  
398 Khouri H, Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM. 2003. Role of mobile  
399 DNA in the evolution of vancomycin-resistant *Enterococcus faecalis*. *Science* 299:2071-4.
- 400 6. Garcia-Solache M, Rice LB. 2019. The Enterococcus: a Model of Adaptability to Its Environment.  
401 *Clin Microbiol Rev* 32.
- 402 7. Poeta P, Costa D, Igrejas G, Sáenz Y, Zarazaga M, Rodrigues J, Torres C. 2007. Polymorphisms of  
403 the *pbp5* gene and correlation with ampicillin resistance in *Enterococcus faecium* isolates of  
404 animal origin. *J Med Microbiol* 56:236-240.

- 405 8. Fontana R, Aldegheri M, Ligozzi M, Lopez H, Sucari A, Satta G. 1994. Overproduction of a low-  
406 affinity penicillin-binding protein and high-level ampicillin resistance in *Enterococcus faecium*.  
407 Antimicrob Agents Chemother 38:1980-3.
- 408 9. Galloway-Pena JR, Rice LB, Murray BE. 2011. Analysis of PBP5 of early U.S. isolates of *Enterococcus*  
409 *faecium*: sequence variation alone does not explain increasing ampicillin resistance over time.  
410 Antimicrob Agents Chemother 55:3272-7.
- 411 10. Pietta E, Montealegre MC, Roh JH, Cocconcelli PS, Murray BE. 2014. *Enterococcus faecium* PBP5-  
412 S/R, the missing link between PBP5-S and PBP5-R. Antimicrob Agents Chemother 58:6978-81.
- 413 11. Ahmed MO, Baptiste KE. 2018. Vancomycin-Resistant Enterococci: A Review of Antimicrobial  
414 Resistance Mechanisms and Perspectives of Human and Animal Health. Microb Drug Resist  
415 24:590-606.
- 416 12. Arias CA, Contreras GA, Murray BE. 2010. Management of multidrug-resistant enterococcal  
417 infections. Clin Microbiol Infect 16:555-62.
- 418 13. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad, II, Rijnders BJ, Sherertz RJ,  
419 Warren DK. 2009. Clinical practice guidelines for the diagnosis and management of intravascular  
420 catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect  
421 Dis 49:1-45.
- 422 14. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an  
423 emerging challenge for clinicians. Clin Infect Dis 52:228-34.
- 424 15. Bi R, Qin T, Fan W, Ma P, Gu B. 2018. The emerging problem of linezolid-resistant enterococci. J  
425 Glob Antimicrob Resist 13:11-19.
- 426 16. Arias CA, Murray BE. 2008. Emergence and management of drug-resistant enterococcal  
427 infections. Expert Rev Anti Infect Ther 6:637-55.

- 428 17. Chacko KI, Sullivan MJ, Beckford C, Altman DR, Ciferri B, Pak TR, Sebra R, Kasarskis A, Hamula CL,  
429 van Bakel H. 2018. Genetic Basis of Emerging Vancomycin, Linezolid, and Daptomycin  
430 Heteroresistance in a Case of Persistent Bacteremia. *Antimicrob Agents Chemother* 62.
- 431 18. Klare I, Fleige C, Geringer U, Thurmer A, Bender J, Mutters NT, Mischnik A, Werner G. 2015.  
432 Increased frequency of linezolid resistance among clinical *Enterococcus faecium* isolates from  
433 German hospital patients. *J Glob Antimicrob Resist* 3:128-131.
- 434 19. Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. 2011. Emergence of  
435 daptomycin-resistant VRE: experience of a single institution. *Infect Control Hosp Epidemiol*  
436 32:391-4.
- 437 20. Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, Hammerum AM, Schaffer K, Burns  
438 K, Murchan S, Novais C, Freitas AR, Peixe L, Del Grosso M, Pantosti A, Werner G. 2018. Update on  
439 prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci  
440 in Europe: Towards a common nomenclature. *Drug Resist Updat* 40:25-39.
- 441 21. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM,  
442 Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamooy Y, Murray BE,  
443 Weinstock GM. 2011. Genetic basis for in vivo daptomycin resistance in enterococci. *N Engl J Med*  
444 365:892-900.
- 445 22. Tran TT, Panesso D, Gao H, Roh JH, Munita JM, Reyes J, Diaz L, Lobos EA, Shamooy Y, Mishra NN,  
446 Bayer AS, Murray BE, Weinstock GM, Arias CA. 2013. Whole-genome analysis of a daptomycin-  
447 susceptible *Enterococcus faecium* strain and its daptomycin-resistant variant arising during  
448 therapy. *Antimicrob Agents Chemother* 57:261-8.
- 449 23. Greene MH, Harris BD, Nesbitt WJ, Watson ML, Wright PW, Talbot TR, Nelson GE. 2018. Risk  
450 Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid-Nonsusceptible  
451 Vancomycin-Resistant Enterococcus. *Open Forum Infect Dis* 5:ofy185.

- 452 24. Contreras GA, Munita JM, Simar S, Luterbach C, Dinh AQ, Rydell K, Sahasrabhojane PV, Rios R,  
453 Diaz L, Reyes K, Zervos M, Misikir HM, Sanchez-Petitto G, Liu C, Doi Y, Abbo LM, Shimose L, Seifert  
454 H, Gudiol C, Barberis F, Pedroza C, Aitken SL, Shelburne SA, van Duin D, Tran TT, Hanson BM, Arias  
455 CA. 2022. Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant  
456 Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I). *Open Forum Infect*  
457 *Dis* 9:ofab616.
- 458 25. Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V. 2014. Ceftaroline  
459 restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant  
460 *Enterococcus faecium*. *Antimicrob Agents Chemother* 58:1494-500.
- 461 26. Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. 2013. Treatment of high-  
462 level gentamicin-resistant *Enterococcus faecalis* endocarditis with daptomycin plus ceftaroline.  
463 *Antimicrob Agents Chemother* 57:4042-5.
- 464 27. Chuang YC, Chen PY, Lin CY, Chen YC, Wang JT, Chang SC. 2018. A retrospective clinical comparison  
465 of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant  
466 *Enterococcus faecium* bloodstream infections. *Sci Rep* 8:1632.
- 467 28. Jahanbakhsh S, Singh NB, Yim J, Kebriaei R, Smith JR, Lev K, Tran TT, Rose WE, Arias CA, Rybak MJ.  
468 2020. Impact of Daptomycin Dose Exposure Alone or in Combination with beta-Lactams or  
469 Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model. *Antimicrob*  
470 *Agents Chemother* 64.
- 471 29. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA.  
472 2012. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of  
473 ampicillin- and vancomycin-resistant *Enterococcus faecium*. *Antimicrob Agents Chemother*  
474 56:838-44.

- 475 30. Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ. 2015. beta-Lactam combinations  
476 with daptomycin provide synergy against vancomycin-resistant *Enterococcus faecalis* and  
477 *Enterococcus faecium*. *J Antimicrob Chemother* 70:1738-43.
- 478 31. Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. 2017. Ceftazidime-Avibactam and  
479 Aztreonam, an Interesting Strategy To Overcome beta-Lactam Resistance Conferred by Metallo-  
480 beta-Lactamases in Enterobacteriaceae and *Pseudomonas aeruginosa*. *Antimicrob Agents*  
481 *Chemother* 61.
- 482 32. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data.  
483 *Bioinformatics* 30:2114-20.
- 484 33. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: Resolving bacterial genome assemblies  
485 from short and long sequencing reads. *PLoS Comput Biol* 13:e1005595.
- 486 34. Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt  
487 KD, Borodovsky M, Ostell J. 2016. NCBI prokaryotic genome annotation pipeline. *Nucleic Acids*  
488 *Res* 44:6614-24.
- 489 35. Jolley KA, Bray JE, Maiden MCJ. 2018. Open-access bacterial population genomics: BIGSdb  
490 software, the PubMLST.org website and their applications. *Wellcome Open Res* 3:124.
- 491 36. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby Larsen M, Lund O, Villa L, Moller Aarestrup F,  
492 Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid  
493 multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895-903.
- 494 37. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham  
495 S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012.  
496 SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J*  
497 *Comput Biol* 19:455-77.

- 498 38. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH,  
499 McDermott PF, Tadesse DA, Morales C, Simmons M, Tillman G, Wasilenko J, Folster JP, Klimke W.  
500 2019. Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial  
501 Resistance Genotype-Phenotype Correlations in a Collection of Isolates. *Antimicrob Agents*  
502 *Chemother* 63.
- 503 39. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL, Rebelo  
504 AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK, Stingl K, Nguyen  
505 M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum MF, Duggett NA, Kempf  
506 I, Nykasenoja S, Olkkola S, Wieczorek K, Amaro A, Clemente L, Mossong J, Losch S, Ragimbeau C,  
507 Lund O, Aarestrup FM. 2020. ResFinder 4.0 for predictions of phenotypes from genotypes. *J*  
508 *Antimicrob Chemother* 75:3491-3500.
- 509 40. Hasman H, Clausen P, Kaya H, Hansen F, Knudsen JD, Wang M, Holzkecht BJ, Samulioniene J,  
510 Roder BL, Frimodt-Moller N, Lund O, Hammerum AM. 2019. LRE-Finder, a Web tool for detection  
511 of the 23S rRNA mutations and the *optrA*, *cfr*, *cfr(B)* and *poxtA* genes encoding linezolid resistance  
512 in enterococci from whole-genome sequences. *J Antimicrob Chemother* 74:1473-1476.
- 513 41. Pincus NB, Bachta KER, Ozer EA, Allen JP, Pura ON, Qi C, Rhodes NJ, Marty FM, Pandit A,  
514 Mekalanos JJ, Oliver A, Hauser AR. 2020. Long-term Persistence of an Extensively Drug-Resistant  
515 Subclade of Globally Distributed *Pseudomonas aeruginosa* Clonal Complex 446 in an Academic  
516 Medical Center. *Clin Infect Dis* 71:1524-1531.
- 517 42. Li H. 2011. A statistical framework for SNP calling, mutation discovery, association mapping and  
518 population genetical parameter estimation from sequencing data. *Bioinformatics* 27:2987-93.
- 519 43. Alikhan NF, Petty NK, Ben Zakour NL, Beatson SA. 2011. BLAST Ring Image Generator (BRIG):  
520 simple prokaryote genome comparisons. *BMC Genomics* 12:402.

- 521 44. Anonymous. 2021. Performance standards for antimicrobial susceptibility testing: 31st  
522 informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
- 523 45. Top J, Willems R, Bonten M. 2008. Emergence of CC17 *Enterococcus faecium*: from commensal to  
524 hospital-adapted pathogen. FEMS Immunol Med Microbiol 52:297-308.
- 525 46. Top J, Willems R, van der Velden S, Asbroek M, Bonten M. 2008. Emergence of clonal complex 17  
526 *Enterococcus faecium* in The Netherlands. J Clin Microbiol 46:214-9.
- 527 47. Lee T, Pang S, Abraham S, Coombs GW. 2019. Antimicrobial-resistant CC17 *Enterococcus faecium*:  
528 The past, the present and the future. J Glob Antimicrob Resist 16:36-47.
- 529 48. Arredondo-Alonso S, Top J, McNally A, Puranen S, Pesonen M, Pensar J, Marttinen P, Braat JC,  
530 Rogers MRC, van Schaik W, Kaski S, Willems RJL, Corander J, Schurch AC. 2020. Plasmids Shaped  
531 the Recent Emergence of the Major Nosocomial Pathogen *Enterococcus faecium*. mBio 11.
- 532 49. Wardal E, Kuch A, Gawryszewska I, Zabicka D, Hryniewicz W, Sadowy E. 2017. Diversity of plasmids  
533 and Tn1546-type transposons among VanA *Enterococcus faecium* in Poland. Eur J Clin Microbiol  
534 Infect Dis 36:313-328.
- 535 50. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. 2002. Gene dosage and linezolid  
536 resistance in *Enterococcus faecium* and *Enterococcus faecalis*. Antimicrob Agents Chemother  
537 46:3334-6.
- 538 51. Chilambi GS, Nordstrom HR, Evans DR, Ferrolino JA, Hayden RT, Maron GM, Vo AN, Gilmore MS,  
539 Wolf J, Rosch JW, Van Tyne D. 2020. Evolution of vancomycin-resistant *Enterococcus faecium*  
540 during colonization and infection in immunocompromised pediatric patients. Proc Natl Acad Sci  
541 U S A 117:11703-11714.
- 542 52. Williams D, Evans B, Haldenby S, Walshaw MJ, Brockhurst MA, Winstanley C, Paterson S. 2015.  
543 Divergent, coexisting *Pseudomonas aeruginosa* lineages in chronic cystic fibrosis lung infections.  
544 Am J Respir Crit Care Med 191:775-85.

